By Josh Beckerman
Biotechnology company Atreca said it is implementing a further reduction in its workforce of about 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.
The company cited financial market conditions and the funding needs required to advance antibody-drug conjugate programs into clinical development.
Atreca also reported a third-quarter loss of 92 cents a share, compared with a loss of 60 cents a share a year earlier.
Write to Josh Beckerman at josh.beckerman@wsj.com